Get the Stockscreener App
440.75
5.59%
23.32
After Hours:
440.75
Madrigal Pharmaceuticals Inc stock is traded at $440.75, with a volume of 474.90K.
It is up +5.59% in the last 24 hours and up +12.60% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$417.43
Open:
$422.07
24h Volume:
474.90K
Relative Volume:
1.27
Market Cap:
$9.79B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-17.55
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
+0.30%
1M Performance:
+12.60%
6M Performance:
+30.19%
1Y Performance:
+89.03%
1-Day Range:
$422.07
$444.27
1-Week Range:
$415.53
$444.27
52-Week Range:
$200.63
$457.16
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
440.75 | 9.30B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.11 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.71 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.17 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
731.77 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
342.89 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Pharmaceuticals announces grants of inducement awards - MarketScreener
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Investment Report: What are Madrigal Pharmaceuticals Incs recent SEC filings showingBull Run & Daily Profit Focused Screening - خودرو بانک
Brokerages Set Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) PT at $483.38 - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
EP Wealth Advisors LLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Rhumbline Advisers Acquires 1,924 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Market Overview: Can Madrigal Pharmaceuticals Inc weather a recession2025 Volume Leaders & Safe Capital Growth Stock Tips - خودرو بانک
Intech Investment Management LLC Has $3.24 Million Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion - MSN
Growth Value: Will Madrigal Pharmaceuticals Inc outperform during market ralliesJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - خودرو بانک
Earnings Recap: Is Madrigal Pharmaceuticals Inc benefiting from innovation trendsStop Loss & Fast Entry and Exit Trade Plans - خودرو بانک
Market Review: What are Madrigal Pharmaceuticals Incs earnings expectationsEarnings Growth Summary & Weekly High Conviction Trade Ideas - خودرو بانک
Pullback Watch: Is Madrigal Pharmaceuticals Inc stock good for income investors2025 Technical Patterns & Daily Growth Stock Tips - خودرو بانک
Madrigal stock jumps 13% after Rezdiffra Q3 sales beat estimates - MSN
Downgrade Watch: What is the next catalyst for ATEXWeekly Gains Summary & Technical Confirmation Alerts - خودرو بانک
Aug PostEarnings: Is Madrigal Pharmaceuticals Inc stock forming a cup and handleLayoff News & Technical Buy Zone Confirmation - خودرو بانک
Short Squeeze: How is Capital City Bank Group Inc. managing supply chain issuesPortfolio Risk Report & Daily Stock Momentum Reports - خودرو بانک
Recap Report: Does Madrigal Pharmaceuticals Inc. stock benefit from AI growthJuly 2025 Patterns & Weekly Consistent Profit Watchlists - خودرو بانک
Woodline Partners LP Raises Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO Sells $3,243,740.77 in Stock - MarketBeat
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s Strong Q2 Sales and EU Approval - Sahm
Canaccord Genuity Group Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - Defense World
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Madrigal Pharmaceuticals stock price target raised by Canaccord on MASH drug outlook - Investing.com Canada
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 12-Month HighTime to Buy? - MarketBeat
What is HC Wainwright's Estimate for MDGL Q3 Earnings? - MarketBeat
Canaccord Genuity Boosts Madrigal Pharmaceuticals (MDGL) Price T - GuruFocus
Don't Ignore The Insider Selling In Madrigal Pharmaceuticals - simplywall.st
Cinctive Capital Management LP Sells 4,315 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
CoreWeave and Madrigal’s Insider Trades Flash Bullish Signals - Investing.com
CoreWeave and Madrigal's Insider Trades Flash Bullish Signals - MarketBeat
Madrigal Pharmaceuticals Grants Equity Awards to New Employees - MSN
Madrigal Pharma CEO Sibold sells $3.24 million in stock By Investing.com - Investing.com Canada
Madrigal Pharma CEO Sibold sells $3.24 million in stock - Investing.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Now Covered by Analysts at HC Wainwright - MarketBeat
Can Madrigal Pharmaceuticals Inc. stock double in the next yearQuarterly Performance Summary & Free Expert Verified Stock Movement Alerts - Lancaster City Council
Can Madrigal Pharmaceuticals Inc. benefit from deglobalizationPortfolio Value Report & Short-Term High Return Ideas - Lancaster City Council
A Fresh Look at Madrigal Pharmaceuticals (MDGL) Valuation Following Recent Share Price Momentum - Yahoo Finance
Cutter Capital Management LP Invests $7.95 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals stock hits all-time high at 443.86 USD By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):